Vascular Disease clinical trials at University of California Health

15 in progress, 10 open to eligible people

Showing trials for

  • Ralinepag to Improve Treatment Outcomes in PAH Patients

    open to eligible people ages 18 years and up

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

    at UC Davis UC Irvine UCLA UCSD

  • BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

    open to eligible people ages 18 years and up

    Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.

    at UCSF

  • Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 55-70

    The objective of the current study is to test the overarching hypothesis that the beef nutritive matrix is uniquely suited to direct dietary zinc to cellular compartments for improved metabolic function, leading to a greater effect on health outcomes. Specifically, whether beef, as a component of a healthy meal, will promote the absorption of zinc into cells, where the zinc will have greater effects on zinc-dependent metabolic processes supporting cardiovascular health. To maximize the observability of these beef-related effects, individuals who are 55- to 70-year-old who generally have a higher risk of zinc deficiency and cardiovascular disease will be enrolled.

    at UC Davis

  • IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

    open to eligible people ages 21 years and up

    The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

    at UCSD UCSF

  • PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    open to eligible people ages 18-95

    A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

    at UCLA UCSD UCSF

  • SELUTION4BTK Trial

    open to eligible people ages 18 years and up

    This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

    at UCLA

  • SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

    open to eligible people ages 18 years and up

    The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.

    at UCSF

  • Factors Affect Outcomes in Cardiovascular Surgery

    “Physicians reviewing medical records to discover factors that affect outcomes in Cardiovascular Surgery”

    open to eligible people ages 18 years and up

    Identify factors that contribute to perioperative morbidity and mortality in patients undergoing cardiac surgery that involves cardiopulmonary bypass. Identify factors that affect perioperative morbidity and mortality in patients undergoing cardiac surgery.

    at UC Davis

  • International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

    open to eligible people ages 18 years and up

    The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its recurrence. This observational study will be prospective and retrospective in its recruitment and will collect clinical information to better understand the natural history and prognosis for SCAD.

    at UCLA

  • Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

    open to eligible people ages up to 21 years

    Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.

    at UCSF

  • Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System for the TREatment of Vascular Lesions Located in the InfrapoplitEal Arteries BeLow the Knee (DEEPER REVEAL)

    Sorry, in progress, not accepting new patients

    This is a prospective, multicenter, single arm study designed to evaluate the safety and efficacy of the Temporary Bare Spur Stent System (Spur Stent System).

    at UC Irvine

  • Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

    Sorry, accepting new patients by invitation only

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

    at UC Davis UC Irvine UCLA UCSD

  • Artificial Intelligence for Early Detection of Peripheral Artery Disease

    Sorry, not yet accepting patients

    The goal of this clinical trial is to test an AI-based screening tool that will help to identify patients at high risk of having undiagnosed peripheral artery disease. The primary outcome measure is overall rate of new PAD diagnoses. Secondary outcomes include rate of new secondary prevention measures initiated for PAD, which will include new prescriptions for antiplatelets, PAD-dosed rivaroxaban, statins, smoking cessation counseling or referrals, and/or supervised exercise therapy referrals also aggregated at a clinic and site level.

    at UCSD

  • PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    Sorry, in progress, not accepting new patients

    The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").

    at UCLA UCSF

  • TORUS 2 IDE Clinical Study

    Sorry, in progress, not accepting new patients

    The primary objective of the TORUS 2 IDE Clinical Study is to evaluate the safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the native SFA or the superficial femoral and/or proximal popliteal arteries.

    at UCSF

Our lead scientists for Vascular Disease research studies include .

Last updated: